Cord Blood Banking Market to Hit $50B

The global cord blood banking market was valued at approximately $27 billion in 2024. Stem cells from cord blood can be used in the treatment of more than 80 different diseases, including various cancers, blood disorders, and immune system deficiencies. Private cord blood banks account for the largest share of the market, with parents paying for collection and ongoing storage fees for their family's exclusive use. However, public banking is experiencing rapid growth, and the American Academy of Pediatrics recommends public donation unless a close family member has a condition that could be treated with the stem cells. The primary driver for the market's expansion is the rising prevalence of cancers like leukemia and lymphoma. To date, more than 35,000 cord blood transplants have been performed globally to treat such blood-related abnormalities. Key players in this fragmented market include Cord Blood Registry (CBR) Systems, Cryo-Cell International, and ViaCord. Advancements in cryopreservation and the integration of AI and blockchain for improved sample management are enhancing the efficiency and security of biobanking operations. While cancer treatment is the leading application, the therapeutic potential of cord blood is expanding. Researchers are conducting trials on using these stem cells to treat conditions like autism spectrum disorder and cerebral palsy, which could significantly increase demand. The Asia-Pacific region is projected to be the fastest-growing market for these services. This growth is fueled by improving healthcare infrastructure, rising disposable incomes, and increasing awareness campaigns in countries like China and India.